{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Medical Devices news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/medical-devices/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/medical-devices/feed.json", "description": "Latest Medical Devices company headlines from United States, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:e721566810d1ae6823af0916d6629004c34bfb90090acbca1d0785244621bb86", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses", "content_text": "Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses", "date_published": "2026-08-14T16:34:23+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Guidance", "ATEC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ATEC", "name": "Alphatec Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/2921f310-82cb-4bea-95f7-9048a8ca02b5/"}]}}, {"id": "source:6c629efa3a3edf577097f19c01abbdeef43ba08bb5cbfedc71d5803efed5ae25", "url": "https://www.nasdaq.com/articles/notable-etf-outflow-detected-spsm-cort-gkos-eat", "external_url": "https://www.nasdaq.com/articles/notable-etf-outflow-detected-spsm-cort-gkos-eat", "title": "Notable ETF Outflow Detected - SPSM, CORT, GKOS, EAT", "content_text": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 600 Small Cap ETF (Symbol: SPSM) where we have detected an approximate $125.1 million dollar outflow -- that's a 0.7% decrease week over week (from 301,210,217 to 299,060,217). Among the largest underlying components of SPSM, in trading today Corcept Therapeutics Inc (Symbol: CORT) is up about 2.3%, Glaukos Corp (Symbol: GKOS) is down about 0.8%, and Brinker International, Inc. (Symbol: EAT) is lower by about 0.4%. For a complete list of holdings,", "date_published": "2026-08-14T15:04:04+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "GKOS"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GKOS", "name": "Glaukos Corp", "sentiment_url": "https://sharemaestro.com/sentiment/e819594c-c2ec-407c-b30a-b300a02a9210/"}]}}, {"id": "source:3ca12183a4b8fdaae81a0dbd2f4e8862aa042d23b16f40222e9bf12880a75edd", "url": "https://seekingalpha.com/news/4633323-smith-nephew-gaap-eps-of-036-revenue-of-16b?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633323-smith-nephew-gaap-eps-of-036-revenue-of-16b?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Smith & Nephew GAAP EPS of $0.36, revenue of $1.6B", "content_text": "* Smith & Nephew press release [https://seekingalpha.com/filing/309951347] (SNN [https://seekingalpha.com/symbol/SNN]): Q2 GAAP EPS of $0.36. * Revenue of $1.6B (+3.2% Y/Y). * Trading profit for the first half reached $566M, an 8.10% increase year-over-year, expanding the trading profit margin by 60 bps to 18.30%. * Cash generated from operations reached $605M. MORE ON SMITH & NEPHEW * Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript [https://seekingalpha.com/article/4929913-smith-and-nephew-plc-snn-q2-2026-earnings-call-transcript] * Smith & Nephew plc 2026 Q2 - Results - Earnings Ca", "date_published": "2026-08-14T14:35:40+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "SNN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNN", "name": "Smith & Nephew SNATS Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ca69f5b7-163b-4513-bb18-82a6766befe6/"}]}}, {"id": "source:852b3b07ad31df79f03ca445f9208d142914d3a00060c060f1b819149361791a", "url": "https://www.globenewswire.com/news-release/2026/08/14/3345452/0/en/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-august-31-2026-in-insulet-corporation-lawsuit-podd.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/14/3345452/0/en/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-august-31-2026-in-insulet-corporation-lawsuit-podd.html", "title": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff", "content_text": "The Gross Law Firm is alerting shareholders of Insulet Corporation (NASDAQ: PODD) about a lead plaintiff deadline of August 31, 2026, in a class action lawsuit. The lawsuit alleges that Insulet made materially false and/or misleading statements regarding defective manufacturing controls that created a risk of product safety violations. Shareholders who purchased PODD shares between February 21, 2025, and May 26, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment.", "date_published": "2026-08-14T14:30:18+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Regulatory and legal", "PODD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/c1a60e73-081a-460a-9198-1d9e143774bc/"}]}}, {"id": "source:701a5ab6e8f3aa07836a63bfd5bb6625190117c83e6221455cca8d9c0e5fecc1", "url": "https://www.globenewswire.com/news-release/2026/08/14/3345368/0/en/attention-long-term-shareholders-of-ars-pharmaceuticals-inc-nasdaq-spry-bloom-energy-corporation-nyse-be-erasca-inc-nasdaq-eras-and-insulet-corporation-nasdaq-podd-grabar-law-offic.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/14/3345368/0/en/attention-long-term-shareholders-of-ars-pharmaceuticals-inc-nasdaq-spry-bloom-energy-corporation-nyse-be-erasca-inc-nasdaq-eras-and-insulet-corporation-nasdaq-podd-grabar-law-offic.html", "title": "Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf", "content_text": "Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which led to significant stock declines for these companies. Long-term shareholders are encouraged to contact the law office to explore options for corporate reforms and recovery of funds.", "date_published": "2026-08-14T13:03:57+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Market update", "PODD"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/c1a60e73-081a-460a-9198-1d9e143774bc/"}]}}, {"id": "source:4ceaa3b51fc3d9f9a56de7b9b52808a8f0bf3901e53299b4beb572429384ff3e", "url": "https://www.marketbeat.com/instant-alerts/west-pharmaceutical-services-nysewst-rating-lowered-to-hold-at-zacks-research-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/west-pharmaceutical-services-nysewst-rating-lowered-to-hold-at-zacks-research-2026-08-14", "title": "West Pharmaceutical Services (NYSE:WST) Rating Lowered to Hold at Zacks Research", "content_text": "Zacks Research downgraded West Pharmaceutical Services (NYSE:WST) from \"strong buy\" to \"hold\" despite the company reporting strong quarterly results, exceeding EPS and revenue estimates. The broader analyst consensus remains a \"Moderate Buy\" with an average price target of $368.08. West Pharmaceutical Services posted Q2 EPS of $2.37 on revenue of $872.3 million, a 13.8% increase year-over-year, and forecast full-year 2026 EPS between $8.85 and $9.05.", "date_published": "2026-08-14T11:40:20+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "STE"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "STE", "name": "STERIS plc", "sentiment_url": "https://sharemaestro.com/sentiment/7b7c4ffa-5b66-43bb-800e-531f7cb23e72/"}]}}, {"id": "source:a2d5c0aa3ce84c6bdb7ccd6744695004be27f5d9088f8f488a9afd7b1fcc2802", "url": "https://www.stocktitan.net/sec-filings/SNN/6-k-smith-nephew-plc-current-report-foreign-issuer-9e7e5c98b5b2.html", "external_url": "https://www.stocktitan.net/sec-filings/SNN/6-k-smith-nephew-plc-current-report-foreign-issuer-9e7e5c98b5b2.html", "title": "Smith+Nephew (SNN) lifts H1 2026 profit but cuts revenue growth outlook", "content_text": "Smith+Nephew reported a higher profit for the first half of 2026, with revenue reaching $3,097 million, an increase of 4.6% year-on-year, and trading profit up 8.1% to $566 million. Despite this profit growth, the company revised its full-year underlying revenue growth guidance downwards from \"around 6%\" to \"around 4%\" due to softer performance in Orthopaedics and Advanced Wound Bioactives. Management reiterated its targets for trading profit growth, free cash flow, and adjusted ROIC, banking on efficiency savings and a stronger second half driven by new product launches and market stabilization.", "date_published": "2026-08-14T11:12:53+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "SNN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNN", "name": "Smith & Nephew SNATS Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ca69f5b7-163b-4513-bb18-82a6766befe6/"}]}}, {"id": "source:cd26016a7fea095ebdaf445e7a44df14f370dafbcbdadc048ae23e61d3054ef0", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQZ1V6X3k2TTIwaXJNUTFUREJzNUFVenIyS1ZaSVdzaTZxTWI4WlFULTdybkFYTTIyeVV5OHkxSWFvTDRtb2pNX0pVcWZ0X0VlWDdtQklqaXdRSWpZOE4zS1V0VVlSZ1lOdFBBUHluTXp6SVlmVHdCTnE1ZFZKamRhV0o2OFVEbjUzM0EwZ3hCeVEzWDZKalRvUmZTZUxwd2Nzdll3WlM0QXRId255WWxxVi1fYzFTYW52SV9nenV3UDNpRjF2d01IMk95QVhTY0V0cmVPQkh6by1PaExw0gHiAUFVX3lxTE92dWJaSFBzZ0RlYzlyLVZGam9MYW5KT2Jzc21WYXFWSTdXSUFOaDFQSTFFQkFZeWtqTk1TRXBoWkxnS0NPNmNfR25wUE8xUkxDaHFnZDNnRTE4NWJ6QzVLTjYwS04tcjUwMDRtYmJ2TU8wbUluRDhUY18xMW83STZJWDZEQUZCTENnYnNDck1iQ2JTcEZQRFNiNXZpWm9pOTZuVzQzYy1UNkE4bDlUbDVVTFNFOXZFYmFYQ2pOQW9pRkpjRl93cHZkVFEyM2lhVmY0aW5RZnQwZ3NKZS1YRXgwMUE?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Lumexa Imaging (LMRI) Stock Jumps As Profit Arrives But Margin Doubts Persist", "content_text": "Lumexa Imaging (LMRI) Stock Jumps As Profit Arrives But Margin Doubts Persist", "date_published": "2026-08-14T10:44:50+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Earnings", "LMRI"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LMRI", "name": "Lumexa Imaging Holdings, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/28da8f7d-c009-4062-bcb4-11f9066859e7/"}]}}, {"id": "source:611c3c7e6d9823abbad41de0d6d89812c8b0824bb262f604ee9ed7202f98c020", "url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-102442230.html", "external_url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-102442230.html", "title": "Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses", "content_text": "Parnassus Investments, an investment management company, released the \"Parnassus Core Equity Fund\" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as well as the fund's lack of Energy exposure, while Financials and Health Care detracted. The fund is positioning for long-term growth through AI infrastructure, semiconductors, electrification and industrial automation, while", "date_published": "2026-08-14T10:24:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "BSX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corp", "sentiment_url": "https://sharemaestro.com/sentiment/486ab989-f120-4769-ae89-ae0116149e46/"}]}}, {"id": "source:45a7b56556a9c3507e5b1510f687ed09542e564cae1b7d7ee9d710ed03151f70", "url": "https://finance.yahoo.com/markets/articles/foam-packaging-market-report-2025-080100105.html", "external_url": "https://finance.yahoo.com/markets/articles/foam-packaging-market-report-2025-080100105.html", "title": "Foam Packaging Market Report 2025\u20132034: Evaluating $33.8 Billion Projection, PE & PU Rigid Foams, and Market Shares of UFP Tech, Zotefoams, Sealed Air, and BASF", "content_text": "Company Logo urging global trade, e-commerce expansion, and strict protective packaging standards highlighted by UFP Technologies' record $174 million Q2 2026 sales, Zotefoams' 23% H1 revenue surge, and strategic scale across Sealed Air and Smurfit Westrock\u2014are propelling the global foam packaging market from $19.1 billion in 2024 to a projected $33.8 billion by 2034 at a 5.9% CAGR. This 187-page study delivers an in-depth analysis across material types (polyethylene, polyurethane, polypropylene, bio-based alternatives), product formats (rigid vs. flexible foams), end-use verticals (electronic", "date_published": "2026-08-14T08:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "UFPT"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "UFPT", "name": "UFP Technologies Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f22dd2e5-d07d-4d85-a57b-3981d51bc50b/"}]}}, {"id": "source:1bf8900ac9187a326cc3fe9c11e2682893974e51db828ea73c39fa521316c728", "url": "https://www.marketbeat.com/instant-alerts/filing-smith-nephew-snats-inc-snn-shares-sold-by-bank-of-america-corp-de-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-smith-nephew-snats-inc-snn-shares-sold-by-bank-of-america-corp-de-2026-08-14", "title": "Smith & Nephew SNATS, Inc. $SNN Shares Sold by Bank of America Corp DE", "content_text": "Bank of America Corp DE reduced its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 12.5% in the first quarter, selling 176,622 shares but still retaining over 1.2 million shares valued at approximately $39.4 million. Despite this sale, several other institutional investors increased their holdings in SNN, with institutions and hedge funds collectively owning 25.64% of the stock. The company has a consensus \"Hold\" rating from analysts with a target price of $30.93 and recently announced a dividend of $0.312 per share.", "date_published": "2026-08-14T07:12:53+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "SNN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNN", "name": "Smith & Nephew SNATS Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ca69f5b7-163b-4513-bb18-82a6766befe6/"}]}}, {"id": "source:cd524511e62e5c9c3dec2c1d35dfc57dc0fd744938fa0435c4b11a6860e4d7de", "url": "https://kalkinemedia.com/us/news/announcements/capsovision-reports-q2-2026-financials-inventory-growth-and-balance-sheet-update", "external_url": "https://kalkinemedia.com/us/news/announcements/capsovision-reports-q2-2026-financials-inventory-growth-and-balance-sheet-update", "title": "CapsoVision Reports Q2 2026 Financials: Inventory Growth and Balance Sheet Update", "content_text": "CapsoVision, Inc. has released its Q2 2026 financial results, highlighting significant inventory growth, increased total assets, and a decrease in cash and cash equivalents. The medical device firm, classified as a non-accelerated filer, reported 50,046,913 shares outstanding and provided forward-looking statements regarding its operations and FDA clearance processes.", "date_published": "2026-08-14T03:40:42+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Earnings", "CV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CV", "name": "CapsoVision, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/acf45639-4b44-4cac-83e2-123074c02146/"}]}}, {"id": "source:350e8b0f908a191d1ec65427f675fa0c0434ffe64637da431ccf76d5a5533ef2", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-syk-still-look-undervalued-031601632.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-syk-still-look-undervalued-031601632.html", "title": "Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Str", "date_published": "2026-08-14T03:16:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "SYK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/6c084548-8fa4-4599-ae27-500f7627c98a/"}]}}, {"id": "source:4194dd28059a5c7c5da8c4a32af73a20ed36586a0c211e4e6851e60f58413e81", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5QX0ZBbFhyVHBOb3NvSTFSLURWZnpBWDQ3TnlOcFZWNE8yaDlXVjUtdlYxQl9XYjJDV0lDcVVXSnVkQVRPSi1BVTQtajZqOHNWa2NrRTQ0bFRiVHVZSVBBSjFudjQ0bDhqaGQ3ZHhsbENRSkNMYzBiZEJKcTRuQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5QX0ZBbFhyVHBOb3NvSTFSLURWZnpBWDQ3TnlOcFZWNE8yaDlXVjUtdlYxQl9XYjJDV0lDcVVXSnVkQVRPSi1BVTQtajZqOHNWa2NrRTQ0bFRiVHVZSVBBSjFudjQ0bDhqaGQ3ZHhsbENRSkNMYzBiZEJKcTRuQQ?oc=5", "title": "iRhythm (IRTC) Q2 2026 Earnings Call Transcript", "content_text": "iRhythm (IRTC) Q2 2026 Earnings Call Transcript", "date_published": "2026-08-14T02:49:42+00:00", "authors": [{"name": "AOL.com"}], "tags": ["Earnings", "IRTC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IRTC", "name": "iRhythm Technologies Inc", "sentiment_url": "https://sharemaestro.com/sentiment/6037d9b6-7ee1-4ace-8dd7-476704dbdcc0/"}]}}, {"id": "source:f4bb09df8d87d5f7ee87f2e52948df9097c459e37193982ab0271b6ea12bb7e2", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-glaukos-nysegkos-coo-sells-60000-shares-of-stock-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/insider-selling-glaukos-nysegkos-coo-sells-60000-shares-of-stock-2026-08-13", "title": "Insider Selling: Glaukos (NYSE:GKOS) COO Sells 60,000 Shares of Stock", "content_text": "Glaukos Corporation's COO, Joseph Gilliam, sold 60,000 shares of company stock for approximately $10.8 million, reducing his direct ownership by 45.25%. The sale occurred while Glaukos shares were trading near a 52-week high, and the company recently reported strong quarterly revenue and beat EPS estimates. Despite the insider selling, analyst sentiment remains largely positive, with a \"Moderate Buy\" consensus and several raised price targets.", "date_published": "2026-08-14T01:40:13+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "GKOS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GKOS", "name": "Glaukos Corp", "sentiment_url": "https://sharemaestro.com/sentiment/e819594c-c2ec-407c-b30a-b300a02a9210/"}]}}, {"id": "source:65c852dc775c72b5502fcdeef2c90a9021dfa62ffb565c8da6ae1009c5ce2d46", "url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-technologies-gehc-stock-011218947.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-technologies-gehc-stock-011218947.html", "title": "GE HealthCare Technologies (GEHC) Stock Still Looks Cheap After A 20% Jump", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. GE HealthCare Technologies stock has climbed 19.7% over the past month, yet its valuation checks still lean toward the shares looking cheap rather than stretched. The 19.7% gain over the past month points to a sharp reset in expectations that puts the current pricing under closer scrutiny for new buyers and existing holders. Recent expansion of ultrasound and breast imaging platforms can support expectations for future revenue, while execution risks around", "date_published": "2026-08-14T01:12:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/524a3188-9d54-4845-a4c2-1736b1e487ad/"}]}}, {"id": "source:0e1a399e0a7001b18ccd6df5057be6d1541a41206be6afd590a2c2e1151e9474", "url": "https://www.nasdaq.com/articles/artivion-aort-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/artivion-aort-q2-2026-earnings-call-transcript", "title": "Artivion (AORT) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chairman, President, and Chief Executive Officer - Pat MackinExecutive Vice President, Chief Operating Officer and Chief Financial Officer - Lance Berry TAKEAWAYS Revenue -- $125.8 million, up 9% on a constant currency basis reflecting growth in heart valve and stent graft products.Adjusted EBITDA -- $26.4 million, a 7% increase year over year driven by higher product sales.EBITDA Margin -- 21%, a decrease of 90 basis points due to increased investments in research and development and the acquisition o", "date_published": "2026-08-14T00:46:49+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "AORT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AORT", "name": "Artivion Inc", "sentiment_url": "https://sharemaestro.com/sentiment/5d8adb4b-b9f3-41c7-bbb7-96d6cd08a6f0/"}]}}, {"id": "source:8514049e63b85f57f6214fbb34024478bb217946a0d6148eebf714fd5bc44b67", "url": "https://m.investing.com/news/insider-trading-news/glaukos-coo-joseph-gilliam-sells-107m-in-stock-93CH-4859571?ampMode=1", "external_url": "https://m.investing.com/news/insider-trading-news/glaukos-coo-joseph-gilliam-sells-107m-in-stock-93CH-4859571?ampMode=1", "title": "Glaukos COO Joseph Gilliam sells $10.7m in stock", "content_text": "Glaukos Corporation's COO, Joseph Gilliam, sold 60,000 shares of company stock for $10.7 million after exercising stock options. These sales occurred when the stock was near its 52-week high, and Gilliam now beneficially owns 72,588 shares. The transactions follow recent strong Q2 2026 financial results for Glaukos, which led to increased price targets from several analyst firms.", "date_published": "2026-08-14T00:40:13+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "GKOS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GKOS", "name": "Glaukos Corp", "sentiment_url": "https://sharemaestro.com/sentiment/e819594c-c2ec-407c-b30a-b300a02a9210/"}]}}, {"id": "source:5177a981c7911be44d5d0fe8c061faec13bf3f6254086dd2c5854a237843064b", "url": "https://seekingalpha.com/news/4632994-capsovision-anticipates-fda-clearance-for-ai-highlights-by-end-of-q3-as-it-targets-q4?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632994-capsovision-anticipates-fda-clearance-for-ai-highlights-by-end-of-q3-as-it-targets-q4?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "CapsoVision anticipates FDA clearance for AI Highlights by end of Q3 as it targets Q4 CapsoCam Colon submission", "content_text": "Earnings Call Insights: CapsoVision, Inc. (CV) Q2 2026 MANAGEMENT VIEW * \u201cThe second quarter represented another period of steady progress for CapsoVision as we continued executing our commercial strategy while advancing several important initiatives across our product portfolio,\u201d said (Co-Founder, President, CEO & Director Kang Wang), citing \u201c10% year-over-year revenue growth,\u201d expanding adoption \u201cacross larger hospital systems and gastroenterology networks,\u201d and \u201cencouraging underlying utilization trends across our installed base.\u201d * (President Wang) highlighted scale of adoption: \u201cAs of Jun", "date_published": "2026-08-14T00:28:04+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "CV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CV", "name": "CapsoVision, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/acf45639-4b44-4cac-83e2-123074c02146/"}]}}, {"id": "source:2119559983d88f54fed2f9b6de7ae9cd6c9c03584d4dbac9d637eb5c0a7d098a", "url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "external_url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "title": "Philips (ENXTAM:PHIA) Expands Open Monitoring Ecosystem And Launches Postpartum Support Tool", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Koninklijke Philips (ENXTAM:PHIA) announces new collaborations to expand its open monitoring ecosystem and connected care offerings. The company introduces the Philips Avent Share the Care Connector to support postpartum mothers with digital tools and guidance. Philips works with health technology partners to extend continuous and out of hospital patient monitoring capabilities. The Share the Care Connector is launched in co", "date_published": "2026-08-14T00:16:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "PHG"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHG", "name": "Koninklijke Philips NV ADR", "sentiment_url": "https://sharemaestro.com/sentiment/b84c69c6-909b-45c2-85cc-316fb2dbc8a9/"}]}}, {"id": "source:6d94a2828794f443fb7600fc36fdf927e9d2536c40861e5a870a9d6ffbb4958c", "url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "title": "Could Danaher Corporation (DHR)\u2019s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?", "content_text": "When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower in response. That drop immediately spilled over to Bio-Rad Laboratories, Inc. (NYSE:BIO), holder of a $5 billion strategic stake in Sartorius, sending Bio-Rad shares down about 1% in early New York trading.", "date_published": "2026-08-14T00:13:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BIO", "BIO-B"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BIO", "name": "Bio-Rad Laboratories Inc", "sentiment_url": "https://sharemaestro.com/sentiment/44578368-5def-4bb4-93a6-9e3af3864587/"}, {"symbol": "BIO-B", "name": "Bio-Rad Laboratories Inc", "sentiment_url": "https://sharemaestro.com/sentiment/d4d96f73-d1a8-45ca-888c-710dd3765e65/"}]}}, {"id": "source:ab2c51771587f41533ea48ec612d1bb39848e4d7b9d03cfbcf18599c8f54438f", "url": "https://www.nasdaq.com/articles/cytosorbents-ctso-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/cytosorbents-ctso-q2-2026-earnings-call-transcript", "title": "Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Phillip ChanExecutive Vice President and Chief Financial Officer - Peter MarianiChief Medical Officer - Efthymios Deliargyris TAKEAWAYS Revenue -- $9.6 million, remaining consistent with the prior year and increasing 9% sequentially from the first quarter.Gross Margin -- 73%, reflecting manufacturing optimization, improved sourcing, and production efficiencies.Adjusted EBITDA Loss -- $1.6 million, representing a 38% improvement compared to a loss of $2.6 million in the prior y", "date_published": "2026-08-13T23:29:56+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "CTSO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CTSO", "name": "Cytosorbents Crp", "sentiment_url": "https://sharemaestro.com/sentiment/7963bbd5-fe62-4802-839d-f37566903b1e/"}]}}, {"id": "source:9b2ffebbfe52332e61e6da3a32ddf36986a5748431a22d56c8529648efc8c054", "url": "https://kalkinemedia.com/us/news/announcements/lumexa-imaging-holdings-reports-q2-2026-earnings-with-return-to-profitability", "external_url": "https://kalkinemedia.com/us/news/announcements/lumexa-imaging-holdings-reports-q2-2026-earnings-with-return-to-profitability", "title": "Lumexa Imaging Holdings Reports Q2 2026 Earnings with Return to Profitability", "content_text": "Lumexa Imaging Holdings Inc. reported a significant financial turnaround for Q2 2026, moving from a net loss of $7,226 thousand in Q2 2025 to a net income of $2,745 thousand. This improvement was driven by increased total revenues and a notable decrease in interest expenses. The company also saw growth in total assets and equity, reflecting a strong first half of 2026.", "date_published": "2026-08-13T23:11:59+00:00", "authors": [{"name": "Kalkine Media"}], "tags": ["Earnings", "LMRI"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LMRI", "name": "Lumexa Imaging Holdings, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/28da8f7d-c009-4062-bcb4-11f9066859e7/"}]}}, {"id": "source:c07919ffe94d371921fe302065a18b3cc75f4c13bf7eea50920ed191510831bc", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPOE81cUlEaTctOEY3azJ4WEQyeDQtWGprVnRQX0cyRXRqTHhWZ1VyWVozSHBLTEsxNDNjRFRCb01sT3Y1d1ZKTjJEVGVzLUNSYXMtYXR3Zi1WcmM2TTFocW0zTUE4Yl9teUhLVml1bE1TSDgtbnM4SmJTZFVsMHFsZThLOEpMTFdBeEE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPOE81cUlEaTctOEY3azJ4WEQyeDQtWGprVnRQX0cyRXRqTHhWZ1VyWVozSHBLTEsxNDNjRFRCb01sT3Y1d1ZKTjJEVGVzLUNSYXMtYXR3Zi1WcmM2TTFocW0zTUE4Yl9teUhLVml1bE1TSDgtbnM4SmJTZFVsMHFsZThLOEpMTFdBeEE?oc=5", "title": "CAPSOVISION ($CV) Releases Q2 2026 Earnings", "content_text": "CAPSOVISION ($CV) Releases Q2 2026 Earnings", "date_published": "2026-08-13T22:51:00+00:00", "authors": [{"name": "Quiver Quantitative"}], "tags": ["Earnings", "CV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CV", "name": "CapsoVision, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/acf45639-4b44-4cac-83e2-123074c02146/"}]}}, {"id": "source:77b6b88f9dfa98351eaeec97554088f931f18810cc1e32a2b54d8b3b9e8be6b4", "url": "https://finance.yahoo.com/healthcare/articles/could-alcon-alc-rxsight-rxst-224910777.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-alcon-alc-rxsight-rxst-224910777.html", "title": "Could Alcon (ALC) and RxSight (RXST)\u2019s Partnership Reshape the Future of Cataract Surgery?", "content_text": "Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight's proprietary light-adjustable technology, which allows eye surgeons to fine-tune a patient's vision using UV light after surgery, with Alcon's global commercial footprint and surgical equipment portfolio, the agreement validates ", "date_published": "2026-08-13T22:49:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RXST"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RXST", "name": "Rxsight Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ecdcbe38-e1c5-4ccf-ad67-0ffa8ce94261/"}]}}, {"id": "source:6b9eb275ea336f3b3a34e8c886d0dc06581c466844f6048c8f7fde9a55dff791", "url": "https://www.nasdaq.com/articles/sanuwave-snwv-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/sanuwave-snwv-q2-2026-earnings-call-transcript", "title": "SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Friday, Aug. 7, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Morgan FrankChief Financial Officer - Peter Sorensen TAKEAWAYS Revenue -- $9.7 million, a 3% decrease from $10.1 million, reflecting a sharp decline in capital equipment sales for SANUWAVE Health, Inc.(NASDAQ:SNWV).UltraMIST Applicator Revenue -- $7.3 million, a 13% increase from $6.4 million, representing the core recurring revenue driver for the business.UltraMIST System Revenue -- $2.3 million, a 34% decline from $3.4 million, driven by financial pressure across ", "date_published": "2026-08-13T22:46:22+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "SNWV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNWV", "name": "SANUWAVE Health, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/f0929ea2-bffc-4811-aad4-35674cb71e2e/"}]}}, {"id": "source:d92841f6c4961ed14825359a4c4468e7c199ffe056ea5141e7d924e78ec9b21b", "url": "https://www.stocktitan.net/sec-filings/DXCM/form-4-dexcom-inc-insider-trading-activity-d64a61dbcbba.html", "external_url": "https://www.stocktitan.net/sec-filings/DXCM/form-4-dexcom-inc-insider-trading-activity-d64a61dbcbba.html", "title": "Dexcom (DXCM) director Augustinos donates 1,075 shares and reports 5,575 RSUs", "content_text": "Dexcom director Nicholas Augustinos reported a gift of 1,075 shares of common stock to a charitable donor-advised fund on August 12, 2026. These shares were held indirectly through the Kirschner/Augustinos Revocable Trust, which now holds 37,382 shares. Additionally, Augustinos holds 5,575 unvested restricted stock units granted on May 28, 2026, set to vest on the earlier of their one-year anniversary or the company's 2027 Annual Meeting of Stockholders.", "date_published": "2026-08-13T22:38:46+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "DXCM"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DXCM", "name": "DexCom Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ebc374af-f110-4556-9f61-3e092b2c4c12/"}]}}, {"id": "source:95b46bc0fd33f91c7cbeb2d9a79677b965b0c783e9077202c2e335a4a270fac7", "url": "https://www.morningstar.com/news/pr-newswire/20260813ny26030/podd-deadline-suewallst-reminds-insulet-corporation-investors-of-upcoming-securities-class-action-deadline", "external_url": "https://www.morningstar.com/news/pr-newswire/20260813ny26030/podd-deadline-suewallst-reminds-insulet-corporation-investors-of-upcoming-securities-class-action-deadline", "title": "PODD DEADLINE: SueWallSt Reminds Insulet Corporation Investors of Upcoming Securities Class Action Deadline", "content_text": "SueWallSt is reminding investors of Insulet Corporation (NASDAQ: PODD) about an upcoming securities class action deadline on August 31, 2026. The lawsuit focuses on alleged defective cannula manufacturing that led to insulin under-delivery in millions of Omnipod devices and caused a significant decline in Insulet's stock price. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, may be eligible for compensation.", "date_published": "2026-08-13T22:09:03+00:00", "authors": [{"name": "Morningstar"}], "tags": ["Regulatory and legal", "PODD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/c1a60e73-081a-460a-9198-1d9e143774bc/"}]}}, {"id": "source:69d672d82d6258487a28c69929c8222c3409286b2c2e408904ffede9cefcb983", "url": "https://seekingalpha.com/news/4632962-co-diagnostics-outlines-fda-dual-510-k-and-clia-waiver-submission-as-cash-falls-to-3_6m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632962-co-diagnostics-outlines-fda-dual-510-k-and-clia-waiver-submission-as-cash-falls-to-3_6m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Co-Diagnostics outlines FDA dual 510(k) and CLIA waiver submission as cash falls to $3.6M", "content_text": "Earnings Call Insights: Co-Diagnostics (CODX) Q2 2026 MANAGEMENT VIEW * Dwight Egan (Chairman, CEO & President) framed Q2 as \u201canother important step in our transition from platform development toward commercialization,\u201d emphasizing \u201cadvancing regulatory milestones, expanding our global commercial opportunities, enhancing our platform capabilities and positioning the company for commercialization.\u201d * Egan highlighted a key regulatory inflection point for the U.S. respiratory program, stating the company \u201cofficially announced the submission of our dual 510(k) and CLIA waiver by application to th", "date_published": "2026-08-13T22:07:49+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "CODX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CODX", "name": "Co-Diagnostics, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/62f9bf27-60c8-4211-bad2-6ec93acad04c/"}]}}, {"id": "source:fcb60258693e27a6cca700e26f69bdcef6ada540b68afc90935ede2aafcb64c2", "url": "https://www.gurufocus.com/stock/MIL:1DXCM/summary", "external_url": "https://www.gurufocus.com/stock/MIL:1DXCM/summary", "title": "DexCom Inc (MIL:1DXCM) Stock Price, Trades & News", "content_text": "This page provides a detailed overview of DexCom Inc (MIL:1DXCM) stock, including its current price, market capitalization, P/E and P/B ratios, and key financial metrics. It highlights the company's financial strength, growth rank, profitability, and GF Value rank, along with recent news and upcoming earnings dates. The company designs and commercializes continuous glucose monitoring systems for diabetic patients.", "date_published": "2026-08-13T22:07:42+00:00", "authors": [{"name": "GuruFocus"}], "tags": ["Earnings", "DXCM"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DXCM", "name": "DexCom Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ebc374af-f110-4556-9f61-3e092b2c4c12/"}]}}, {"id": "source:851f0f20de66eb95b25630dd76853de0f48d957172994d2e07627d87733b8c97", "url": "https://www.globenewswire.com/news-release/2026/08/13/3345028/9788/en/bronstein-gewirtz-grossman-llc-urges-insulet-corporation-investors-to-act-class-action-filed-alleging-investor-harm.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/13/3345028/9788/en/bronstein-gewirtz-grossman-llc-urges-insulet-corporation-investors-to-act-class-action-filed-alleging-investor-harm.html", "title": "Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm", "content_text": "Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and its officers, alleging violations of federal securities laws. The lawsuit claims that Insulet made materially false and misleading statements about its manufacturing controls and procedures, creating a foreseeable risk of safety regulation violations. Investors who purchased Insulet securities between May 21, 2025, and May 26, 2026, are encouraged to join the case and have until August 31, 2026, to request to be appointed as lead plaintiff.", "date_published": "2026-08-13T21:54:48+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Regulatory and legal", "PODD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/c1a60e73-081a-460a-9198-1d9e143774bc/"}]}}, {"id": "source:c7254f9d4c0f9111414557a1a3dd63b862e10191155e055f133a0e29c3d61759", "url": "https://www.marketscreener.com/news/capsovision-files-mixed-shelf-for-up-to-250-million-in-securities-ce7859ded881f22c", "external_url": "https://www.marketscreener.com/news/capsovision-files-mixed-shelf-for-up-to-250-million-in-securities-ce7859ded881f22c", "title": "CapsoVision Files Mixed Shelf for Up to $250 Million in Securities", "content_text": "CapsoVision, Inc. has filed a mixed shelf registration for up to $250 million in securities, as reported on August 13, 2026. This financial move allows the company flexibility in raising capital through various securities offerings in the future. The announcement coincides with other recent company news, including its Q2 2026 earnings call and an international launch of AI highlights for its CapsoCam Plus System.", "date_published": "2026-08-13T21:19:00+00:00", "authors": [{"name": "www.marketscreener.com"}], "tags": ["Earnings", "CV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CV", "name": "CapsoVision, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/acf45639-4b44-4cac-83e2-123074c02146/"}]}}, {"id": "source:16eed49a1a06fe1c190ea2e413be1d5ab59941a6d65946d23129357fb3b6e0b8", "url": "https://seekingalpha.com/news/4632932-capsovision-inc-gaap-eps-of-0_15-misses-by-0_02-revenue-of-3_64m-misses-by-0_17m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632932-capsovision-inc-gaap-eps-of-0_15-misses-by-0_02-revenue-of-3_64m-misses-by-0_17m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "CapsoVision, Inc. GAAP EPS of -$0.15 misses by $0.02, revenue of $3.64M misses by $0.17M", "content_text": "* CapsoVision, Inc. press release [https://seekingalpha.com/pr/20619065-capsovision-reports-second-quarter-2026-financial-results] (CV [https://seekingalpha.com/symbol/CV]): Q2 GAAP EPS of -$0.15 misses by $0.02. * Revenue of $3.64M (+9.6% Y/Y) misses by $0.17M. MORE ON CAPSOVISION, INC. * Seeking Alpha\u2019s Quant Rating on CapsoVision, Inc. [https://seekingalpha.com/symbol/CV/ratings/quant-ratings] * Historical earnings data for CapsoVision, Inc. [https://seekingalpha.com/symbol/CV/earnings] * Financial information for CapsoVision, Inc. [https://seekingalpha.com/symbol/CV/income-statement]", "date_published": "2026-08-13T21:18:26+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "CV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CV", "name": "CapsoVision, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/acf45639-4b44-4cac-83e2-123074c02146/"}]}}, {"id": "source:9867d95c34f9f0ac846bac6790f1fb737b533c0a873fec72d6a8a0e26a432788", "url": "https://www.marketwatch.com/data-news/ge-healthcare-technologies-inc-stock-rises-thursday-outperforms-market-ea331226-a3fc63518428", "external_url": "https://www.marketwatch.com/data-news/ge-healthcare-technologies-inc-stock-rises-thursday-outperforms-market-ea331226-a3fc63518428", "title": "GE HealthCare Technologies Inc. stock rises Thursday, outperforms market", "content_text": "GE HealthCare Technologies Inc. (GEHC) stock rose 2.09% on Thursday, closing at $73.79. This performance outpaced the broader market, with the S&P 500 Index gaining 0.65% and the Dow Jones Industrial Average rising 0.13%. The increase broke a two-day losing streak for the company's stock.", "date_published": "2026-08-13T20:58:00+00:00", "authors": [{"name": "MarketWatch"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/524a3188-9d54-4845-a4c2-1736b1e487ad/"}]}}, {"id": "source:5ace9146f311b81cedb0541548607e74f1c1a3ef94c1b309b39ccb73285e8118", "url": "https://www.stocktitan.net/sec-filings/ZBH/schedule-13g-a-zimmer-biomet-holdings-inc-amended-passive-investment--666406f9fe54.html", "external_url": "https://www.stocktitan.net/sec-filings/ZBH/schedule-13g-a-zimmer-biomet-holdings-inc-amended-passive-investment--666406f9fe54.html", "title": "Zimmer Biomet (ZBH) sees Dodge & Cox disclose 12.5% ownership stake", "content_text": "Dodge & Cox has filed an amended Schedule 13G, revealing a 12.5% beneficial ownership stake in Zimmer Biomet Holdings, Inc. (ZBH), as of June 30, 2026. This represents 24,124,735 shares, with Dodge & Cox holding sole voting power over 22,808,935 shares and sole dispositive power over all 24,124,735 shares. The filing also notes that Dodge & Cox Stock Fund accounts for 8.0% of the outstanding common stock, and clients retain rights to dividends and sale proceeds.", "date_published": "2026-08-13T20:53:37+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "ZBH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZBH", "name": "Zimmer Biomet Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f0f7e97b-995d-4dfa-9467-ede594723a0f/"}]}}, {"id": "source:ac3971c84b6f25ac48d54afe94bf51b94fba0dd2048cfe182491bde21308d014", "url": "https://www.stocktitan.net/sec-filings/IART/schedule-13g-a-integra-lifesciences-holdings-corp-amended-passive-inv-56368fb7b614.html", "external_url": "https://www.stocktitan.net/sec-filings/IART/schedule-13g-a-integra-lifesciences-holdings-corp-amended-passive-inv-56368fb7b614.html", "title": "Paradigm Capital discloses 4.42% Integra LifeSciences (IART) stake with sole voting control", "content_text": "Paradigm Capital Management, Inc. has reported an amended stake in Integra LifeSciences Holdings Corp (IART), disclosing beneficial ownership of 3,439,098 shares, which represents 4.42% of the outstanding common stock. The New York S corporation maintains sole voting and dispositive power over all these shares. This filing characterizes their holding as ownership of 5 percent or less of the class, aligning with regulatory reporting thresholds.", "date_published": "2026-08-13T20:41:33+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "IART"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IART", "name": "Integra LifeSciences Holdings", "sentiment_url": "https://sharemaestro.com/sentiment/25cf2d83-9f86-4566-96b3-056cc96859b9/"}]}}, {"id": "source:ab708a8bd93fa9993a2e0e3914ca7e21b5a3e7a4dc5c9c46fea5b2fd17c63d5b", "url": "https://www.stocktitan.net/sec-filings/CODX/10-q-co-diagnostics-inc-quarterly-earnings-report-d0227d310c9d.html", "external_url": "https://www.stocktitan.net/sec-filings/CODX/10-q-co-diagnostics-inc-quarterly-earnings-report-d0227d310c9d.html", "title": "Co-Diagnostics (CODX) posts Q2 loss and flags going concern, raises new equity", "content_text": "Co-Diagnostics (CODX) reported significant losses and minimal revenue for Q2 2026, leading management to flag substantial doubt about its ability to continue as a going concern without additional capital. The company posted a net loss of $6.3 million for the quarter and $15.4 million year-to-date, with cash and cash equivalents dwindling to $3.6 million. To address liquidity issues, CODX raised $7.1 million through an at-the-market equity program and a private placement, alongside subsequent warrant exercises.", "date_published": "2026-08-13T20:41:18+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Balance sheet", "CODX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CODX", "name": "Co-Diagnostics, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/62f9bf27-60c8-4211-bad2-6ec93acad04c/"}]}}, {"id": "source:9bbbc39caefd33ac52099d717a118704c83cff89bd646f001b5f205cbc8eef33", "url": "https://www.stocktitan.net/sec-filings/CV/10-q-capso-vision-inc-quarterly-earnings-report-4c0c374befb0.html", "external_url": "https://www.stocktitan.net/sec-filings/CV/10-q-capso-vision-inc-quarterly-earnings-report-4c0c374befb0.html", "title": "CapsoVision (CV) widens losses in H1 2026 and flags going concern risk", "content_text": "CapsoVision (CV) reported widened losses in the first half of 2026, with a net loss of $14.51 million and cash and cash equivalents of $9.08 million against $14.47 million used in operating activities. Despite raising $14 million in a March 2026 private placement and establishing a $100 million at-the-market equity program, management expressed substantial doubt about the company's ability to continue as a going concern within one year without additional capital. The company is advancing its CapsoCam Colon capsule towards a 510(k) submission in Q4 2026 and anticipates FDA clearance for AI enhancements to CapsoCam Plus by the end of Q3 2026.", "date_published": "2026-08-13T20:40:42+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Balance sheet", "CV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CV", "name": "CapsoVision, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/acf45639-4b44-4cac-83e2-123074c02146/"}]}}, {"id": "source:c07d3e007d4ef194fc3e3139f7b19d63be68a40d39c4dcafaa30bfd3ae678349", "url": "https://www.stocktitan.net/sec-filings/MOBI/schedule-13g-mobia-medical-inc-passive-investment-disclosure-5-f5b338354203.html", "external_url": "https://www.stocktitan.net/sec-filings/MOBI/schedule-13g-mobia-medical-inc-passive-investment-disclosure-5-f5b338354203.html", "title": "Mobia Medical (MOBI) investors report up to 11.6% ownership in Schedule 13G", "content_text": "U.S. Venture Partners XII, L.P., Presidio Management Group XII, L.L.C., and Casey M. Tansey have filed a Schedule 13G disclosing significant ownership stakes in Mobia Medical, Inc. (MOBI). U.S. Venture Partners XII, L.P. holds 5.7%, Presidio Management Group XII, L.L.C. holds 10.9%, and Casey M. Tansey, a board member, holds 11.6% of the company's common stock. These filings indicate beneficial ownership with shared voting and dispositive powers, based on 33,249,006 outstanding shares as of June 1, 2026.", "date_published": "2026-08-13T20:39:35+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "MOBI"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MOBI", "name": "Mobia Medical, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/462c8f54-31b5-48ab-9dcd-36d650637918/"}]}}, {"id": "source:299e9e54650d00473e14f0dda0582c84251285e0fa1c7d9d650b0ead45b19df0", "url": "https://www.nasdaq.com/articles/which-small-cap-etf-better-buy-ishares-growth-focused-iwo-or-invescos-revenue-weighted-rwj", "external_url": "https://www.nasdaq.com/articles/which-small-cap-etf-better-buy-ishares-growth-focused-iwo-or-invescos-revenue-weighted-rwj", "title": "Which Small-Cap ETF Is the Better Buy: iShares' Growth-Focused IWO or Invesco's Revenue-Weighted RWJ?", "content_text": "Key Points The iShares Russell 2000 Growth ETF manages $15 billion in assets, providing significantly higher liquidity than the $138 million Invesco S&P SmallCap 600 Revenue ETF. Invesco S&P SmallCap 600 Revenue ETF has outperformed over the past 12 months with a 37% return, compared to 34% for the iShares fund. The iShares Russell 2000 Growth ETF offers broader diversification with over 1,000 holdings, while the Invesco fund maintains a concentrated basket of 127 stocks.10 stocks we like better than iShares Trust - iShares Russell 2000 Growth ETF \u203a The iShares Russell 2000 Growth ETF(NYSEMKT:", "date_published": "2026-08-13T20:39:01+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "GKOS"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GKOS", "name": "Glaukos Corp", "sentiment_url": "https://sharemaestro.com/sentiment/e819594c-c2ec-407c-b30a-b300a02a9210/"}]}}, {"id": "source:262e2a4190c49192f8747cb01e6087d77097fde7c33e61b1a9cb1c20d610c0db", "url": "https://www.stocktitan.net/sec-filings/SINT/schedule-13g-sintx-technologies-inc-passive-investment-disclosure-5-fca5e31d8655.html", "external_url": "https://www.stocktitan.net/sec-filings/SINT/schedule-13g-sintx-technologies-inc-passive-investment-disclosure-5-fca5e31d8655.html", "title": "Bleichroeder discloses 9.99% SINTX Technologies (SINT) stake with warrant limits", "content_text": "Bleichroeder LP and related entities have disclosed a 9.99% beneficial ownership stake in SINTX Technologies Inc. (SINT) via a Schedule 13G filing. This stake, totaling 647,513 common shares, includes both currently held shares and shares issuable upon the exercise of warrants, which are subject to a 9.99% beneficial ownership limitation. Without this limitation, Bleichroeder would beneficially own 1,569,039 shares, representing 21.19% of SINTX's outstanding common stock.", "date_published": "2026-08-13T20:15:36+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "SINT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SINT", "name": "SINTX Technologies Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bf5f44e9-8347-42d1-bf3d-e76d2c9d6fbd/"}]}}, {"id": "source:c4a8bf4349d238d9df8e09303ac3a8793f3848741e00a6edf2e67b0a7234d0d5", "url": "https://www.stocktitan.net/sec-filings/UFPT/144-ufp-technologies-inc-sec-filing-8bd9fee11bc2.html", "external_url": "https://www.stocktitan.net/sec-filings/UFPT/144-ufp-technologies-inc-sec-filing-8bd9fee11bc2.html", "title": "UFP Technologies (UFPT) insider files Form 144 to sell 1,000 shares", "content_text": "An insider at UFP Technologies (UFPT) has filed a Form 144 to sell 1,000 shares of common stock through Merrill Lynch, with an anticipated sale date of August 13, 2026, on NASDAQ. The filing indicates the seller previously received stock awards for compensation in 2023, 2024, and 2025, and had already sold 1,200 shares on June 12, 2026. This action is categorized with a neutral filing impact and sentiment.", "date_published": "2026-08-13T20:12:30+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "UFPT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UFPT", "name": "UFP Technologies Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f22dd2e5-d07d-4d85-a57b-3981d51bc50b/"}]}}, {"id": "source:2bb5d24e186697894091cfa62adf0f819198ae8d5cf8f92df822808df725563a", "url": "https://seekingalpha.com/news/4632782-quantum-si-gaap-eps-of-0_11-beats-by-0_01-revenue-of-0_34m-beats-by-0_04m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4632782-quantum-si-gaap-eps-of-0_11-beats-by-0_01-revenue-of-0_34m-beats-by-0_04m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Quantum-Si GAAP EPS of -$0.11 beats by $0.01, revenue of $0.34M beats by $0.04M", "content_text": "* Quantum-Si press release [https://seekingalpha.com/pr/20619102-quantum-si-reports-second-quarter-2026-financial-results-and-provides-proteus-development] (QSI [https://seekingalpha.com/symbol/QSI]): Q2 GAAP EPS of -$0.11 beats by $0.01. * Revenue of $0.34M (-42.4% Y/Y) beats by $0.04M. * For the full year 2026, the Company reiterated the following financial guidance, as initially issued on March 3, 2026: Revenue: Approximately $1.0 million Adjusted total operating expenses: $98.0 million or less Total cash usage: $93.0 million or less Click to enlarge MORE ON QUANTUM-SI * Quantum-Si Incorpor", "date_published": "2026-08-13T20:12:25+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "QSI"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "QSI", "name": "QuantumSi Inc", "sentiment_url": "https://sharemaestro.com/sentiment/40c7d749-3095-4d63-90c9-f86cb81776bd/"}]}}, {"id": "source:9111ecd6d52f7111084fb95b483b745810157adc823e0331489a2fddcfe5948d", "url": "https://www.prnewswire.com/news-releases/co-diagnostics-reports-second-quarter-2026-financial-results-302851294.html", "external_url": "https://www.prnewswire.com/news-releases/co-diagnostics-reports-second-quarter-2026-financial-results-302851294.html", "title": "Co-Diagnostics Reports Second Quarter 2026 Financial Results", "content_text": "Co-Diagnostics, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $0.17 million and a net loss of $6.3 million. The company highlighted significant operational progress, including advancing manufacturing in Saudi Arabia, expanding commercial outreach in Europe and Latin America, submitting an FDA 510(k) application for its Flu A/B & RSV test, and strengthening its integrated Co-Dx PCR platform.", "date_published": "2026-08-13T19:41:18+00:00", "authors": [{"name": "PR Newswire"}], "tags": ["Earnings", "CODX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CODX", "name": "Co-Diagnostics, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/62f9bf27-60c8-4211-bad2-6ec93acad04c/"}]}}, {"id": "source:e01ec62281432f4a8cd91b65a4c5c14ea584ca3a3336e47fa3b3262a65b9e411", "url": "https://www.globenewswire.com/news-release/2026/08/13/3344916/0/en/capsovision-reports-second-quarter-2026-financial-results.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/13/3344916/0/en/capsovision-reports-second-quarter-2026-financial-results.html", "title": "CapsoVision Reports Second Quarter 2026 Financial Results", "content_text": "CapsoVision reported second-quarter 2026 revenue of $3.6 million, a 10% increase year-over-year, driven by a 13% rise in CapsoCam Plus capsule sales. The company launched its AI Highlights\u2122 feature internationally and anticipates FDA clearance for the U.S. market by the end of Q3 2026, alongside advancing its pipeline products CapsoCam Colon\u2122 and CapsoCam UGI. Despite revenue growth, gross margin decreased to 51% due to competitive market pressures and increased costs from trade policies and tariffs, resulting in a net loss of $7.481 million for the quarter.", "date_published": "2026-08-13T19:40:42+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Earnings", "CV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CV", "name": "CapsoVision, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/acf45639-4b44-4cac-83e2-123074c02146/"}]}}, {"id": "source:908e107d42ce8cd46948d65a3d3176783389114f46c9f0fb3c5af8814e39b564", "url": "https://www.stocktitan.net/sec-filings/LIVN/form-4-liva-nova-plc-insider-trading-activity-991b9682f54c.html", "external_url": "https://www.stocktitan.net/sec-filings/LIVN/form-4-liva-nova-plc-insider-trading-activity-991b9682f54c.html", "title": "LivaNova (LIVN) executive exercises 12,692 SARs and disposes shares", "content_text": "LivaNova PLC's Chief Innovation Officer, Ahmet Tezel, exercised 12,692 Stock Appreciation Rights (SARs) at a base price of $52.68 per share. Concurrently, 8,589 shares were withheld to cover the SARs base price, 1,428 shares for tax liability, and 2,675 shares were sold on the open market at a weighted-average price of $77.7355. After these transactions, Tezel holds 12,691 SARs and 6,090 ordinary shares.", "date_published": "2026-08-13T19:40:18+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "LIVN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LIVN", "name": "LivaNova PLC", "sentiment_url": "https://sharemaestro.com/sentiment/561f63ea-bea0-4ff9-9798-90913c9668d6/"}]}}, {"id": "source:eb8d32537916312e97bafca18641db9eb940b0aea9bec1f79127025e04949542", "url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-ai-ultrasound-launches-191308464.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-ai-ultrasound-launches-191308464.html", "title": "How GE HealthCare\u2019s New AI Ultrasound Launches Could Shape GEHC\u2019s Diagnostic Edge for Investors", "content_text": "Earlier this month, GE HealthCare introduced the LOGIQ e Xi and LOGIQ e Si laptop ultrasound systems and launched the Invenia ABUS Prime and ABUS StreamVue breast imaging solutions, expanding its AI-enabled and cloud-connected ultrasound portfolio across multiple care settings. These product launches aim to standardize imaging workflows, support remote reading, and address dense-breast screening needs, potentially strengthening GE HealthCare's position in high-value, technologically advanced diagnostics. We'll now examine how this expansion in AI-powered, workflow-focused ultrasound solutions ", "date_published": "2026-08-13T19:13:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/524a3188-9d54-4845-a4c2-1736b1e487ad/"}]}}, {"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOQ244T1kzcjhvckw1RTJkMWFOTVZleDZZZXBiUDlwWXpiUUY2c1htUlJKUGNqc3QycF9tWHFUZUVRd1kwdlBxQ1UzRGFTYV9xTGlNUC1sQWN2NW9JOHBNNEdub1dBY0Z3NVRKc04tOUt0ZWcwV1B0NmU3TlV5ZGNCa0R2SGtxbFZ1VTZqcE1adTRPZTM3TWw5eHlfaVZQUzVrdmQ0bU1LelZRS190aFhuSXpQanBWbWdWdlIxaVVfQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOQ244T1kzcjhvckw1RTJkMWFOTVZleDZZZXBiUDlwWXpiUUY2c1htUlJKUGNqc3QycF9tWHFUZUVRd1kwdlBxQ1UzRGFTYV9xTGlNUC1sQWN2NW9JOHBNNEdub1dBY0Z3NVRKc04tOUt0ZWcwV1B0NmU3TlV5ZGNCa0R2SGtxbFZ1VTZqcE1adTRPZTM3TWw5eHlfaVZQUzVrdmQ0bU1LelZRS190aFhuSXpQanBWbWdWdlIxaVVfQQ?oc=5", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/6c084548-8fa4-4599-ae27-500f7627c98a/"}]}}, {"id": "source:84980dbc017c4e1caacf816c96701866d11ab80a0313de34674c2e716016b3b7", "url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "title": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?", "content_text": "Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/6c084548-8fa4-4599-ae27-500f7627c98a/"}]}}, {"id": "source:244e49ff005a068ab08a7c98d6917683f94fa19dc5eb742699689f75b3548f59", "url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "title": "Koninklijke Philips (ENXTAM:PHIA) Following Exor Stake Update Still Looks Close To Fair Value", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Koninklijke Philips (ENXTAM:PHIA) has drawn renewed attention after updating its long-term agreement with Exor. The move allows Exor to raise its shareholding to 22%, while existing governance arrangements remain unchanged. See our latest analysis for Koninklijke Philips. At a share price of \u20ac23.19, Koninklijke Philips has seen a small pullback over the past month with a 1 month share price return of a 3.74% decline, although the 3 year total shareholder return of 31.21% points to a stro", "date_published": "2026-08-13T17:11:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PHG"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHG", "name": "Koninklijke Philips NV ADR", "sentiment_url": "https://sharemaestro.com/sentiment/b84c69c6-909b-45c2-85cc-316fb2dbc8a9/"}]}}]}